1	Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme
2	Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in
3	South Korea: A nationwide study
4	
5	Ju Hwan Kim Pharm.D <sup>a,*</sup> , Yeon-Hee Baek, B.A <sup>a,*</sup> , Hyesung Lee M.S <sup>a</sup> , Young June Choe
6	M.D, Ph.D <sup>b</sup> , Hyun Joon Shin M.D, Sc.D <sup>c</sup> Ju-Young Shin Ph.D <sup>a, d</sup>
7	
8	*These authors contributed equally to this work as co-first authors
9	
10	<sup>a</sup> School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
11	<sup>b</sup> Division of Infectious Diseases, Department of Social and Preventive Medicine, Hallym
12	University College of Medicine, Chuncheon, Republic of Korea
13	<sup>c</sup> Department of Medicine, Brigham and Women's Hospital, Department of Global Health and
14	Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
15	<sup>d</sup> Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan
16	University, Seoul, Republic of Korea
17	
18	Short title: ACEIs or ARBs use and COVID-19
19	
20	Acknowledgement: The authors appreciate healthcare professionals dedicated to treating
21	COVID-19 patients in Korea, and the Ministry of Health and Welfare, the Health Insurance
22	Review & Assessment Service, and Do-Yeon Cho of the Health Insurance Review &
23	Assessment Service of South Korea for sharing invaluable national health insurance claims
24	data in a prompt manner.
25	Funding: This study was supported by the Government-wide R&D Fund project for

26	infectious disease research through the Government-wide R&D Fund for Infectious Disease
27	Research (GFID) funded by the Korea Health Industry Development Institute of Republic of
28	Korea (No. HG18C0068).
29	
30	Disclosures: Dr. JY Shin report receipt of research funding from the Ministry of Food and
31	Drug Safety, Ministry of Health and Welfare, and National Research Foundation of Republic
32	of Korea; grants from pharmaceutical companies including Amgen, Pfizer, Hoffmann-La
33	Roche, Dong-A ST, Yungjin outside the submitted work.
34	No other disclosures were reported.
35	
36	Address for Correspondence: Ju-Young Shin, PhD, Assistant Professor
37	School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon,
38	Gyeonggi-do 16419, Republic of Korea; E-mail: <u>shin.jy@skku.edu</u>

### 39 Abstract

40 There is ongoing debate as to whether angiotensin-converting enzyme inhibitors (ACEIs) or 41 angiotensin-receptor blockers (ARBs) use is associated with poor prognosis of coronavirus 42 disease-2019 (COVID-19). We sought to investigate the association between ACEI/ARB use 43 and risk of poor clinical outcomes from COVID-19. We identified 1,290 patients with 44 hypertension, of which 682 had recorded ACEI/ARB use and 608 without the use during 30 days preceding the date of COVID-19 diagnosis in completely enumerated COVID-19 cohort 45 46 in South Korea. Our primary endpoint was the clinical outcomes comprised of all-cause 47 mortality, use of mechanical ventilation, intensive care unit (ICU) admission, and sepsis. We 48 used inverse probability of treatment weighting (IPTW) to mitigate selection bias, and 49 Poisson regression model to estimate the relative risks (RR) and 95% confidence intervals 50 (CI) to compare outcomes in ACEI/ARB users with non-users. Compared to non-use, 51 ACEI/ARB use was associated with lower clinical outcomes (IPTW adjusted RR, 0.60; 95% 52 CI, 0.42-0.85; p=0.0046). When assessed by individual outcomes, ACEI/ARB use was not 53 associated with all-cause mortality (IPTW adjusted RR, 0.62; 95% CI, 0.35-1.09; p=0.0973) 54 and respiratory events (IPTW adjusted RR, 0.99; 95% CI, 0.84-1.17; p=0.9043). Subgroup 55 analysis showed a trend toward protective role of ACEIs and ARBs against overall outcomes 56 in men (IPTW adjusted RR, 0.84; 95% CI, 0.69-1.03; p-for-interaction=0.008) and with pre-57 existing respiratory disease (IPTW adjusted RR, 0.74; 95% CI, 0.60-0.92; p-forinteraction=0.0023). We present clinical evidence to support continuing ACE/ARB use in 58 59 completely enumerated hypertensive COVID-19 cohort in South Korea.

60

61 Keywords: COVID-19; hypertension; angiotensin-converting enzyme inhibitors;
62 angiotensin-receptor blockers.

## 63 Introduction

The rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute 64 respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing pandemic, having infected 65 >2,800,000 people over 213 countries as of April 28, 2020<sup>1</sup>. Concerns have been raised 66 regarding poor prognosis of COVID-19 associated with the use of angiotensin-converting 67 enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs)<sup>2</sup>. ACEIs and ARBs 68 were shown to upregulate ACE2 expression and activity in several experimental studies <sup>3-5</sup>. 69 70 Given that the binding of ACE2 and viral spike protein of SARS-CoV-2 allows coronavirus 71 entry into host cells, it had been hypothesized that potential upregulation of ACE2 owing to use of ARBs leads to an increased risk of severe and fatal health outcomes <sup>2,6</sup>. 72

In theory, patients with hypertension being managed with ACEIs or ARBs could be at increased risk of COVID-19 since increased ACE2 by these drug classes may increase viral entry into cells. Alternatively, increased ACE2 had been recognized to counterbalance the pro-inflammatory and vasoconstrictive effect of ACE, mainly through conversion of angiotensin II (Ang II) to Ang-(1-7), a peptide with potential protective anti-inflammatory properties that counterbalances pro-inflammatory activity of Ang II <sup>7-9</sup>.

79 In view of these two opposing mechanistic hypotheses, demands for clinical research 80 remain very high. To date, several observational studies claimed that the use of ACEI/ARB was not associated with increased all-cause mortality <sup>10-14</sup>. However, these studies were 81 limited due to methodological issues in study design, with the former lacking causal 82 83 relationship assessment and latter suffering from immortal time bias arising from 84 misclassification of exposure period. Given the lack of robust population-based study 85 assessing the association between the use of ACEI/ARB and sequelae of COVID-19, we analyzed completely enumerated hypertensive COVID-19 cohort in South Korea to assess 86 87 whether the use of ACEIs and ARBs are associated with poor clinical outcomes from

### 88 COVID-19.

#### 89 Methods

90 We retrieved healthcare database from the Health Insurance Review & Assessment 91 Service of South Korea, which covers over 50 million entire South Korean population, from 92 January 1, 2015 to April 8, 2020. We used completely enumerated database of 69,793 93 subjects who underwent COVID-19 screening test in South Korea. The database contains 94 both inpatient and outpatient prescriptions, demographic (age, sex, and insurance type) and 95 clinical information on visit dates for hospitalization and ambulatory cares, procedures, and diagnosis records coded using Korea Standard Classification of Diseases, 7th revision (K 96 CD-7), which is based on International Classification of Diseases, 10<sup>th</sup> revision (ICD-10). 97 98 The overall agreement of diagnostic records of hypertension, stroke, and heart disease was 93.73%, 98.80%, and 97.93%, respectively <sup>15</sup>. 99

100 We conducted a retrospective cohort study of ACEI/ARB use and adverse outcomes 101 from COVID-19 among patients with hypertension. We identified patients with laboratory 102 confirmed diagnosis of COVID-19 between December 1, 2019 and April 8, 2020. Diagnoses 103 were made based on the diagnostic results from on reverse transcription polymerase chain 104 reaction (RT-PCR) method targeting the RNA-dependent RNA polymerase (RdRP), N, and E genes as recommended by the interim guidance of World Health Organization <sup>16</sup>. Cohort 105 106 entry was defined as the date of incident diagnosis of COVID-19. We required patients to 107 have a recorded diagnosis of hypertension within a 5-year lookback period from the cohort 108 entry.

Exposure to ACEIs and ARBs was ascertained within 30 days preceding the cohort entry. Our exposure of interest was patients ever prescribed with ACEIs or ARBs either as a monotherapy or combination therapy. Non-users were those who had no prescription record of either ACEIs or ARBs during the exposure ascertainment period.

Our study outcomes included clinical outcomes indicative of poor prognosis for COVID-19, comprised of all-cause mortality, use of mechanical ventilation, intensive care unit (ICU) admission, or sepsis. We also assessed all-cause mortality and respiratory events (acute respiratory distress syndrome, interstitial lung disease, pneumonia, and respiratory failure) individually as the secondary endpoints. Each patient was followed until the occurrence of outcome of interest or data-censoring date.

119 We assessed baseline characteristics within 1 year before cohort entry. To make 120 propensity score we used baseline confounders which include age at cohort entry, sex, 121 income level, CHA DS -VASc score, medical history (including diabetes, cardiovascular 122 disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, 123 chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including 124 other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha 125 blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-126 lowering agents, and antianginal agents), dialysis, and the duration of hypertension (<1 year, 127  $\geq 1$  year and < 3 years,  $\geq 3$  years and < 5 years, and  $\geq 5$  years). The treatments for COVID-19 128 (including antibiotics, antivirals, antimalarials (chloroquine and hydroxychloroquine), 129 corticosteroids, and intravenous immunoglobulin) were assessed but not included in the 130 propensity score model as they act as the intermediates between exposure and outcome of our 131 study.

We estimated propensity scores for receiving ACEIs or ARBs by fitting a multivariable logistic regression model using all pre-defined covariates assessed 1 year before cohort entry. We used inverse probability of treatment weighting (IPTW) based on the propensity scores to mitigate selection bias by the characteristics between ACEI/ARB users and non-users. IPTW creates a pseudo population, where the weighted exposure and comparator groups are representative of the patient characteristics in the overall population,

and thus generates the population average treatment effect <sup>17</sup>. We summarized baseline 138 139 characteristics of the study cohort using counts and proportions or mean for categorical or 140 continuous variables, respectively. We used Poisson regression model to estimate relative 141 risk (RR) and corresponding 95% confidence intervals (CI) of each outcome in ACEI/ARB 142 users compared to non-users in patients with COVID-19. The unweighted model was 143 adjusted for pre-defined covariates including age, sex, CHA DS -VASc score, diabetes, 144 CVD, and baseline respiratory diseases for parsimony. These covariates were also used in the 145 IPTW weighted models for doubly robust estimation of causal effect. We chose adjusted 146 IPTW weighted model as a main model to report the RRs and corresponding 95% CIs for the 147 clinical outcomes in ACEI/ARB users, compared with non-user.

148 Given that ACEIs and ARBs, apart from hypertension, are primarily prescribed for 149 patients with diabetes and CVD, we repeated analysis with the restricted cohort of patients 150 with these health conditions to exclude confounding by indication. To evaluate whether the 151 association differed by underlying patients' conditions, we conducted additional subgroup 152 analysis using the interaction terms by age group, sex, CHA DS -VASc score, pre-existing 153 respiratory disease, and hospitalization after diagnosis of COVID-19. In subgroup analysis, 154 we used overall outcomes which include all-cause mortality, use of mechanical ventilation, 155 ICU admission, sepsis, or the occurrence of respiratory events to increase the statistical 156 power. Additionally, we conducted sensitivity analysis where we redefined exposure 157 assessment window as within 180 days preceding the cohort entry to address potential 158 exposure misclassification.

Our study complies with the Declaration of Helsinki and the study protocol was approved by the Institutional Review Board (IRB) of Sungkyunkwan University (SKKU 2020-03-021) and obtaining informed consent was waived by the IRB.

162 **Results** 

163 Among 5,707 patients with confirmed diagnosis of COVID-19, there were 1,290 164 patients with past medical history of hypertension, of which 682 had recorded use of 165 ACEI/ARB and 608 without the use during 30 days preceding cohort entry (Figure 1). The 166 characteristics of the ACEI/ARB users compared with non-users are described in Table 1. 167 Compared to non-users, ACEI/ARB users were older (mean age (standard deviation) 62.8 168 years (14.4) vs. 61.3 years (16.6)), had higher proportion of men (53.4% vs. 49.8%), higher 169 prevalence of hyperlipidemia (38.6% vs. 33.6%), diabetes (37.0% vs. 25.7%), CVD (27.9% vs. 26.0%), chronic kidney disease (18.8% vs. 15.6%) and duration of hypertension over 5 170 171 years (56.7% vs. 41.5%). Concomitant use of other anti-hypertensives was generally similar 172 between ACEI/ARB users and non-users, while the mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was higher 173 in ACEI/ARB users (2.7 vs. 2.4).

174 During the study period, there were 23 (3.4%) and 28 (4.6%) cases of clinical 175 outcomes in ACEI/ARB users and non-users, respectively (Table 2). Compared to non-use, 176 ACEI/ARB use was associated with lower clinical outcomes that included all-cause mortality, 177 mechanical ventilation, ICU admission, and sepsis (IPTW adjusted RR, 0.60; 95% CI, 0.42-178 0.85; p=0.0046). When assessed by individual outcome event, ACEI/ARB use was not 179 associated with the risk of all-cause mortality (IPTW adjusted RR, 0.62; 95% CI, 0.35-1.09; 180 p=0.0973) and respiratory events (IPTW adjusted RR, 0.99; 95% CI, 0.84-1.17; p=0.9043) 181 compared with non-use.

We conducted sensitivity analysis where we redefined the exposure risk window as 180 days preceding the cohort entry to account for potential exposure misclassification (**Table 3**). There were 28 (3.7%) and 23 (4.4%) cases of adverse outcomes in ACEI/ARB users and non-users, respectively. The results from sensitivity analysis were generally consistent with the main analysis; ACEI/ARB use was associated with lower clinical outcomes (IPTW adjusted RR, 0.65; 95% CI, 0.46-0.90; p=0.0094), all-cause mortality

(IPTW adjusted RR, 0.41; 95% CI, 0.25-0.68; p=0.0006), but was not associated with respiratory events (IPTW adjusted RR, 0.94; 95% CI, 0.81-1.09; p=0.4188) compared with non-use.

191 Subgroup analysis on the risk of clinical outcomes compared with non-use is 192 presented in Figure 2. When assessed by exposure subtypes, no significant interaction 193 between the subtypes and the overall outcomes was found (p for interaction=0.015); ACEI 194 (IPTW adjusted RR, 0.67; 95% CI, 0.42-1.06) and ARB use (IPTW adjusted RR, 0.97; 95% 195 CI, 0.83-1.13) was not associated with the risk of overall adverse outcomes. Interestingly, 196 interaction-term analysis showed a trend toward protective role of ACEIs and ARBs against 197 overall outcomes in men (IPTW adjusted RR, 0.84; 95% CI, 0.69-1.03; p for 198 interaction=0.008), with pre-existing respiratory disease (IPTW adjusted RR, 0.74; 95% CI, 199 0.60-0.92; p for interaction=0.0023) and in patients hospitalized for COVID-19 (IPTW 200 adjusted RR, 0.93; 95% CI, 0.78-1.10; p for interaction<0.0001).

# 201 Discussion

202 To the best of our knowledge, this retrospective cohort study provides the first 203 completely enumerated hypertensive COVID-19 cohort study in a national scale. We used 204 medical claims data of patients diagnosed with COVID-19 in South Korea to demonstrate 205 that ACEI/ARB use was not associated with poor clinical outcomes from COVID-19 among 206 patients with hypertension. Specifically, ACEI/ARB use, compared with non-use, was 207 associated with lower clinical outcomes that comprised of all-cause mortality, use of 208 mechanical ventilation, ICU admission, and sepsis. To account for exposure misclassification, 209 we conducted sensitivity analysis to assess exposure status during a period of 180 days 210 preceding the cohort entry in which the IPTW adjusted RRs were largely consistent with the 211 findings from main analysis across all outcome measures. Furthermore, the results from 212 subgroup analysis accounting for potential confounding by indication also remained largely

213 consistent with the findings from main analysis.

214 While the underlying pathogenic link between hypertension and COVID-19 remains 215 to be elucidated, concerns have been raised that ACEIs and ARBs, mainstay of therapy for 216 hypertension and diabetes, may contribute to the adverse outcomes observed in COVID-19 patients<sup>2</sup>. Indeed, interaction between SARS-CoV-2 and ACE2 was proposed a potential 217 mechanism for COVID-19's cell entry <sup>18</sup>, and administration of ACEIs and ARBs 218 upregulated ACE2 expression and activity in several experimental studies <sup>3-5</sup>, which may 219 220 theoretically predispose patients on ACEIs or ARBs at greater risk of COVID-19. Conversely, 221 beneficial role of ACE2 in COVID-19 had been reported, of which a recent pilot clinical trial 222 in acute respiratory distress syndrome demonstrated the promising role of recombinant human ACE2 in attenuating the acute lung injury <sup>19</sup>. Moreover, experimental evidence 223 224 indicates that ARBs, specifically losartan, restored the expression level of ACE2 which was 225 downregulated in pre-clinical models of experimental SARS-CoV infection and acute lung injury <sup>3,20,21</sup>. While there is an ongoing debate on whether to continue or halt ACEI/ARB in 226 227 COVID-19 patients with hypertension, real-world data from our study complement the 228 position statements made by the medical societies such as European Society of Cardiology 229 council, American College of Cardiology, American Heart Association, and Heart Failure Society of America on continuing the use of ACEIs or ARBs as prescribed <sup>22,23</sup>, as 230 231 ACEI/ARB use was not associated with poor clinical outcomes from COVID-19.

232 Consistent with our study finding, several recently published studies also have 233 demonstrated no harm or even protective role of ACEI/ARB in COVID-19. A study in Italy 234 utilized case-control design that involved 6,272 COVID-19 cases and 30,579 matched 235 controls to report that ACEI/ARB use was not associated with the risk of COVID-19 236 (adjusted OR, 0.95; 95% CI, 0.86-1.05)<sup>13</sup>. The most recent single tertiary center-based study 237 in the United States also reported null association between ACEI/ARB use and poor

outcomes from COVID-19 among 2,573 hypertensive COVID-19 patients, with the median 238 239 difference in percentage points between ACEI/ARB users and non-users of -0.5% (95% CI, -4.3-3.2)<sup>14</sup>. Although methodological issues inherent in observational studies limit the 240 241 interpretation of the study findings, study conclusions of these recently published studies are 242 consistent with the findings of our study, and provide clinical evidence that ACEI/ARB use, 243 at least, are not associated with increased risk of poor clinical outcomes from COVID-19. In 244 addition to the observed protective role of ACEIs and ARBs during COVID-19, our subgroup 245 analysis showed a greater benefit with regard to clinical outcomes from COVID-19 in 246 association with ACEI/ARB use than with non-use in men, with pre-existing respiratory 247 disease, and in patients hospitalized for COVID-19. These subgroups had been reported to have poor prognosis in COVID-19<sup>13</sup>, and our study findings should be interpreted with 248 249 caution as we used overall outcomes to increase the statistical power in assessing the role of 250 ACEI/ARB among these subgroups. Additional aspect to be noted in our subgroup analysis is 251 that proportion of patients taking ARBs were notably higher compared with ACEIs as 252 regional hypertension management guideline in Korea recommended ARBs over ACEIs due to more favorable adherence and less frequent adverse events <sup>24</sup>. 253

254 Our study provided clinical evidence indicating ACEI/ARB use not associated with 255 poor prognosis of COVID-19. We generated practicable evidence which addresses the urgent 256 public health need in the uncertainty of clinical consequences of ACEI/ARB use among 257 patients with COVID-19. Second, our results have a solid external validity by assembling 258 completely enumerated COVID-19 cases that occurred in South Korea. South Korea have 259 implemented rigorous screening, contact tracing and quarantine measures, conducting a total of 601,660 COVID-19 screening tests as of April 27 to proactively contain COVID-19<sup>25</sup>. All 260 261 individuals with epidemiologic links with suspected or confirmed COVID-19 patients or 262 came from abroad have been self-quarantined for 14 days, and those who developed a fever

(37.5°C and above) or respiratory symptoms received COVID-19 screening tests <sup>26</sup>; thus, underdiagnosis of COVID-19 is likely to be minimal. Third, our study results were consistent in the subgroup analysis by pre-existing diabetes or CVD, which suggests the robustness of our results from confounding by indication given that ACEIs and ARBs are primarily prescribed for patients with these coexisting comorbidities.

268 Our study also has some limitations. First, potential misclassification of diagnosisbased outcomes (sepsis and respiratory events) may present. Nevertheless, a validation study 269 270 comparing diagnoses in the South Korean healthcare database with electronic medical records reported an overall positive predictive value of 82% <sup>27</sup>. Death records and procedure 271 272 codes including mechanical ventilation and ICU admission have high validity, and thus less 273 likely to affect our study conclusion. Second, there is a potential exposure misclassification 274 owing to short exposure ascertainment period. We found consistent result with the main 275 analysis when the exposure risk window was redefined as 180 days. Third, residual 276 confounding from unmeasured confounders (e.g. smoking history, body mass index, baseline 277 blood pressure and laboratory test results) may have affected our results given inherent 278 limitation of available variables in the analysis of health claims data. Finally, we included 279 prevalent users of ACEI/ARB, while ideally new-user design is recommended where all 280 study subjects are naïve to previous use of ACEI/ARB to address potential under 281 ascertainment of events that occur early in therapy and to precisely control for confounders that may be altered by the study drug  $^{28}$ . However, we used a prevalent user cohort of 282 283 ACEI/ARB given that a new-user design would exclude the large number of subjects that 284 may represent clinically relevant subset.

In conclusion, our study findings did not identify increased risk of adverse outcomes with the use of ACEIs or ARBs among COVID-19 patients with hypertension. We present

- 287 clinical evidence to support current medical societies recommendation on continuing ACEIs
- 288 or ARBs as prescribed in COVID-19 patients.

289

## References

**1.** World Health Organization Coronavirus disease (COVID-19) Situation Dashboard. World Health Organization: World Health Organization, 2020.

**2.** Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nature reviews Cardiology* 2020.

**3.** Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* 2005;111:2605-2610.

**4.** Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, Hoffman A, Abassi Z. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. *Am J Physiol Heart Circ Physiol* 2005;289:H1351-1358.

**5.** Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension* 2004;43:970-976.

**6.** Lia Y CX, Zeng Q, Chen Z, Wang Z, Yuan J, Wang X, Zhou Z, Wei Y, Cao G. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province. *J Clin Cardiol* 2020;36:201-203.

**7.** Rodrigues Prestes TR, Rocha NP, Miranda AS, Teixeira AL, Simoes ESAC. The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research. *Curr Drug Targets* 2017;18:1301-1313.

**8.** Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT(2) receptor and tissue injury: therapeutic implications. *Curr Hypertens Rep* 2014;16:416.

**9.** Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. *BMJ* 2020;369:m1313.

**10.** Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020.

**11.** Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res* 2020.

**12.** Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect* 2020;9:757-760.

**13.** Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med* 2020.

**14.** Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med* 2020.

**15.** Kim YY, Park JH, Kang HJ, Lee EJ, Ha S, Shin SA. Level of Agreement and Factors Associated With Discrepancies Between Nationwide Medical History Questionnaires and Hospital Claims Data. *J Prev Med Public Health* 2017;50:294-302.

**16.** Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020: World Health Organization, 2020.

**17.** Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. *Circulation Cardiovascular quality and outcomes* 2013;6:604-611.

**18.** Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020;181:281-292 e286.

**19.** Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit Care* 2017;21:234.

**20.** Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005;11:875-879.

**21.** Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005;436:112-116.

**22.** Position statement of the ESC Council on Hypertension on ACE-inhibitors and anigotensin receptor blockers. European Society of Cardiology, 2020.

23. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-

19. American Heart Association, 2020.

24. Kim SH, Shin DW, Kim S, Han K, Park SH, Kim YH, Jeon SA, Kwon YC. Prescribing

Patterns of Antihypertensives for Treatment-Naive Patients in South Korea: From Korean NHISS Claim Data. *Int J Hypertens* 2019;2019:4735876.

25. Coronavirus Disease-19, Republic of Korea. Central Disaster Management Headquarters:

Ministry of health and welfare, Republic of Korea, 2020.

**26.** Tackling COVID-19—Health, Quarantine and Economic Measures: Korean Experience.

Ministry of Economy and Finance, Republic of Korea, 2020.

**27.** Screening for osteoporosis: U.S. preventive services task force recommendation statement. *Annals of internal medicine* 2011;154:356-364.

**28.** Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *American journal of epidemiology* 2003;158:915-920.

# Table 1. Characteristics of ACEI/ARB users and non-users in hypertensive COVID-19

patients

	Overall Cohort	ACEI/ARB use	Non-use
Characteristics	(n=1,290)	(n=682)	(n=608)
Age years, mean (SD)	62.1 (15.5)	62.8 (14.4)	61.3 (16.6)
<40	114 (8.8)	42 (6.2)	72 (11.8)
40-64	582 (45.1)	325 (46.7)	257 (42.3)
65-84	517 (40.1)	273 (40.0)	244 (40.1)
≥85	77 (6.0)	42 (6.2)	35 (5.8)
Male, N (%)	667 (51.7)	364 (53.4)	303 (49.8)
Medical History, N (%)			
Hyperlipidemia	467 (36.2)	263 (38.6)	204 (33.6)
Diabetes	408 (31.6)	252 (37.0)	156 (25.7)
Cancer	138 (10.7)	62 (9.1)	76 (12.5)
Respiratory disease	432 (33.5)	222 (32.6)	210 (34.5)
Asthma	132 (10.2)	59 (8.7)	73 (12.0)
COPD	283 (21.9)	137 (20.1)	146 (24.0)
Bronchiectasis	15 (1.2)	10 (1.5)	5 (0.8)
Pneumonia	143 (11.1)	83 (12.2)	60 (9.9)
Interstitial lung disease	16 (1.24)	8 (1.2)	8 (1.3)
Cardiovascular disease	348 (27.0)	190 (27.9)	158 (26.0)
Peripheral vascular disease	113 (8.8)	64 (9.4)	49 (8.1)
Coronary artery disease	150 (11.6)	72 (10.6)	78 (12.8)
Atrial fibrillation	40 (3.1)	19 (2.8)	21 (3.5)
Valvular heart disease	10 (0.8)	8 (1.2)	2 (0.3)
Heart failure	100 (7.8)	59 (8.7)	41 (6.7)
Arrhythmia	38 (3.0)	18 (2.6)	20 (3.3)
Chronic kidney disease	223 (17.3)	128 (18.8)	95 (15.6)
Chronic liver disease	164 (12.7)	80 (11.7)	84 (13.8)
Stroke	137 (10.6)	63 (9.2)	74 (12.2)
Other cerebrovascular diseases	87 (6.7)	44 (6.5)	43 (7.1)
Comedications, N (%)			
CCBs	476 (36.9)	228 (33.4)	248 (40.8)
Diuretics	282 (21.9)	149 (21.9)	133 (21.9)
β-blockers	368 (28.5)	182 (26.7)	186 (30.6)
Alpha blockers	187 (14.5)	106 (15.5)	81 (13.3)
CHA <sub>2</sub> DS <sub>2</sub> -VASc score, mean (SD)	2.5 (1.6)	2.7 (1.4)	2.4 (1.7)
0-1	371 (28.8)	148 (21.7)	223 (36.7)
2-5	860 (66.7)	507 (74.3)	353 (58.1)
6-9	59 (4.6)	27 (4.0)	32 (5.3)
Duration of hypertension, N (%)			<u> </u>
<1 year	114 (8.8)	40 (5.9)	74 (12.2)
$\geq 1$ year and $< 3$ years	247 (19.2)	106 (15.5)	141 (23.2)
$\geq$ 3 years and <5 years	290 (22.5)	149 (21.9)	141 (23.2)
$\geq$ 5 years	639 (49.5)	387 (56.7)	252 (41.5)

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019; SD, standard deviation; COPD, chronic obstructive pulmonary disease; CCBs, calcium channel blockers.

	No. of patients         No. of events           cchanical ventilation         608         28           682         23         608         12           608         12         682         10           608         108         108         108	No. of	Event	Unweighted model		IPTW weighted model*	
		Event rate (%)	Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)	Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)	
All-cause mortality, me	chanical ve	entilation,	ICU admiss	sion, sepsis			
Non-use	608	28	4.6	1.00	1.00	1.00	1.00
ACEIs or ARBs use	682	23	3.4	0.73 (0.42-1.27)	0.71 (0.41-1.24)	0.60 (0.42-0.85)	0.60 (0.42-0.85) <sup>§</sup>
All-cause mortality							
Non-use	608	12	2.0	1.00	1.00	1.00	1.00
ACEIs or ARBs use	682	10	1.5	0.74 (0.32-1.72)	0.71 (0.31-1.67)	0.64 (0.37-1.12)	0.62 (0.35-1.09)
<b>Respiratory events<sup>‡</sup></b>							
Non-use	608	108	17.8	1.00	1.00	1.00	1.00
ACEIs or ARBs use	682	126	18.5	1.04 (0.80-1.35)	1.02 (0.79-1.32)	0.99 (0.84-1.16)	0.99 (0.84-1.17)

Table 2. Relative risks of clinical outcomes in ACEI/ARB users compared to non-users in in hypertensive COVID-19 patients

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019; IPTW, inverse probability of treatment weighting; RR, relative risk; CI, confidence interval; ICU, intensive care unit.

\*To make IPTW, age at cohort entry, sex, income level, CHA  $\Box$ DS  $\Box$ -VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years) were used.

<sup>†</sup>For adjusted RR, multivariable Poisson regression was used and adjusted for age, sex, CHA2DS2-VASc score, diabetes, cardiovascular disease, and respiratory disease.

<sup>‡</sup>Respiratory events include acute respiratory distress syndrome, interstitial lung disease, pneumonia, and respiratory failure.

<sup>§</sup>p-value <0.05

**Table 3.** Sensitivity analysis with redefined exposure risk window of 180 days preceding the cohort entry for the relative risks of clinical

outcomes in ACEI/ARB users comp	ared to non-users in hyp	pertensive COVID-19 patients

	No. of	No. of	Event -	Unweighted model		IPTW weighted model*	
	patients	events	rate (%)	Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)	Crude RR (95% CI)	Adjusted RR <sup>†</sup> (95% CI)
All-cause mortality, mechanical ventilation, ICU admission, sepsis							
Non-use	523	23	4.4	1.00	1.00	1.00	1.00
ACEIs or ARBs use	767	28	3.7	0.83 (0.48-1.44)	0.79 (0.45-1.38)	$0.68 (0.49 - 0.94)^{\$}$	0.65 (0.46-0.90) <sup>§</sup>
All-cause mortality							
Non-use	523	12	2.3	1.00	1.00	1.00	1.00
ACEIs or ARBs use	767	10	1.3	0.57 (0.25-1.32)	0.52 (0.22-1.22)	0.45 (0.27-0.74) <sup>§</sup>	0.41 (0.25-0.68) <sup>§</sup>
<b>Respiratory events<sup>‡</sup></b>							
Non-use	523	92	17.6	1.00	1.00	1.00	1.00
ACEIs or ARBs use	767	142	18.5	1.05 (0.81-1.37)	1.08 (0.77-1.32)	0.98 (0.84-1.13)	0.94 (0.81-1.09)

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019; IPTW, inverse probability of treatment weighting; RR, relative risk; CI, confidence interval; ICU, intensive care unit.

\*To make IPTW, age at cohort entry, sex, income level, CHA  $\Box$ DS  $\Box$ -VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years) were used.

<sup>†</sup>For adjusted RR, multivariable Poisson regression was used and adjusted for age, sex, CHA2DS2-VASc score, diabetes, cardiovascular disease, and respiratory disease.

<sup>‡</sup>Respiratory events include acute respiratory distress syndrome, interstitial lung disease, pneumonia, and respiratory failure. <sup>§</sup>p-value <0.05


## **Figure legends**

**Figure 1.** Description of data source and selection of hypertensive COVID-19 cohort Abbreviations: HIRA, Health Insurance Review & Assessment Service; COVID-19, coronavirus disease 2019; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Figure 2. Relative risks (95% confidence intervals) of overall adverse outcomes in ACEI/ARB users compared to non-users in selected population subgroups Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; IPTW, inverse probability of treatment weighting; CI, confidence interval \*Overall outcomes include all-cause mortality, use of mechanical ventilation, admission to intensive care unit, sepsis, or the occurrence of respiratory events.

<sup>†</sup>Relative risks were adjusted for age, sex, CHA2DS2-VASc score, diabetes, cardiovascular disease, and respiratory disease.

<sup>‡</sup> To make IPTW, age at cohort entry, sex, income level, CHA  $\Box$  DS  $\Box$ -VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and the duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5 years, and  $\geq$ 5 years). Figure 1. Description of data source and selection of hypertensive COVID-19 cohort



Abbreviations: HIRA, Health Insurance Review & Assessment Service; COVID-19, coronavirus disease 2019; ACEI, angiotensin converting

enzyme inhibitor; ARB, angiotensin II receptor blocker.

# Figure 2. Relative risks (95% confidence intervals) of overall clinical outcomes\* in

	No. of	Event rates		IDTW meichted		
Characteristics	patients	ACEI/ ARB	Non- user	IPTW weighted relative risks (95% CI) <sup>*, z</sup>		р
Age group						
-39	114	2.38	8.33	┝╋───┼─┥	0.32 (0.07-1.41)	0.13
40-64	582	14.46	13.23	│ ┝┲→	1.33 (1.00-1.78)	0.05
65-84	517	26.37	27.46	│ ⊢∎╢	0.85 (0.69-1.05)	0.14
≥85	77	40.48	40.00		0.96 (0.61-1.50)	0.86
p for interaction				I T	0.3209	
Sex						
Male	667	19.23	23.76		0.84 (0.69-1.03)	0.09
Female	623	21.07	16.07		1.14 (0.90-1.44)	0.29
p for interaction				│ │ │	0.008	
Drug subtypes						
ARBs	642	20.4	19.90		0.97 (0.83-1.13)	0.67
ACEIs	37	16.22	19.90	⊦∰•	0.67 (0.42-1.06)	0.09
p for interaction				│ ⊢∎→	0.1524	
CHA2DS2-VASc score						
0-1	371	12.84	13.45		0.86 (0.56-1.31)	0.48
2-5	860	21.10	23.51	⊢∎⊣	0.95 (0.80-1.13)	0.54
6-9	59	40.74	25.00	⊢ <b>∰</b> -i	1.39 (0.74-2.64)	0.31
p for interaction					0.6854	
Pre-existing diabetes or CVD						
Yes	621	22.07	20.87		1.07 (0.87-1.33)	0.52
No	669	17.78	19.21		0.83 (0.66-1.04)	0.11
p for interaction					0.1344	
Pre-existing respiratory disease				i .eu		
Yes	432	26.58	31.42		0.74 (0.60-0.92)	0.01
No	858	16.96	13.82		1.23 (0.98-1.53)	0.07
p for interaction					0.0023	
Hospitalization for COVID-19				│ ┞╋┥		
Yes	612	34.15	34.15		0.93 (0.78-1.10)	0.40
						0.80
No	678	7.28	7.17		1.05 (0.73-1.50)	
p for interaction				0.25 0.5 1.0 2.0 4.0	<.0001	

ACEI/ARB users compared to non-users in selected population subgroups

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; IPTW, inverse probability of treatment weighting; CI, confidence interval \*Overall clinical outcomes include all-cause mortality, use of mechanical ventilation, admission to intensive care unit, sepsis, or the occurrence of respiratory events.

<sup>†</sup>Relative risks were adjusted for age, sex, CHA2DS2-VASc score, diabetes, cardiovascular

disease, and respiratory disease.

<sup>‡</sup> To make IPTW, age at cohort entry, sex, income level, CHA  $\Box$  DS  $\Box$ -VASc score, medical history (including diabetes, cardiovascular disease (CVD), stroke, other cerebrovascular disease, hyperlipidemia, respiratory disease, chronic kidney disease, cancer, thromboembolism, and dementia), comedications (including other antihypertensives (calcium channel blockers (CCBs), diuretics,  $\beta$ -blockers, and alpha blockers), antidiabetics, antibiotics, antiarrhythmics, antiplatelets, anticoagulants, lipid-lowering agents, and antianginal agents), dialysis, and the duration of hypertension (<1 year,  $\geq$ 1 year and <3 years,  $\geq$ 3 years and <5

years, and  $\geq 5$  years).